Advertisement

Purinergic Signalling

, Volume 15, Issue 3, pp 367–374 | Cite as

Role of purinergic receptors in hepatobiliary carcinoma in Pakistani population: an approach towards proinflammatory role of P2X4 and P2X7 receptors

  • Arun Asif
  • Madiha Khalid
  • Sobia ManzoorEmail author
  • Hassam Ahmad
  • Aman Ur Rehman
Original Article

Abstract

The primary malignancy of liver, known as hepatocellular carcinoma (HCC), comprises 9% of all hepatobiliary carcinomas. A steady rise has also been observed in adenocarcinoma (ADC) of the liver and ampullary carcinoma (AMC), ascending to 0.5% of gastrointestinal malignancies. Hepatobiliary carcinomas consist of 13% of all cancer occurrences worldwide. Purinergic receptor–based signaling holds the therapeutic potential based on its role in cell proliferation of several carcinomas. An altered ATP concentration in nanomoles may lead towards crucial changes in cancer growth patterns in liver tissue. A total of 40 tissue samples were collected (20 samples of HCC, 10 samples of ADC, and 10 samples of AMC) from patients that underwent surgery. P2X4 and P2X7 receptors exhibited significantly increased expression in HCC, ADC, and AMC samples as compared with the control tissue samples. While ADC and AMC samples showed higher expression of P2X4 and P2X7 than the control, statistically, HCC samples exhibited the most significant expression of both P2X4 and P2X7 receptors than control tissues. It may be inferred that higher expression of P2X4 and P2X7 receptors is significantly associated with the upregulated cellular stress leading to inflammation and it is plausible that both these receptors may be used in diagnostic, prognostic, and therapeutic tools for carcinoma studies in the future.

Keywords

Inflammatory precursor Purinergic signaling Hepatocellular carcinoma Cancer microenvironment 

Notes

Acknowledgments

We are thankful to the Higher Education Commission and NUST for providing the opportunity to conduct this research work. We are also thankful to Liver Transplant Unit of Shaikh Zayd Hospital, Lahore, in coordinating this research work.

Compliance with ethical standards

The designed study was duly reviewed and approved by the ethics committee of Shaikh Zayd Hospital, Lahore, and Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, in accordance with the recommendations of the World Medical Association’s Declaration of Helsinki for biomedical experimentation involving human subjects.

Conflict of interest

Arun Asif declares that he has no conflict of interest.

Madiha Khalid declares that she has no conflict of interest.

Sobia Manzoor declares that she has no conflict of interest.

Hassam Ahmad declares that he has no conflict of interest.

Aman-ur-Rehman declares that he has no conflict of interest.

Research involving human participants and/or animals

This article involved liver biopsy samples from human participants, and does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, Jemal A (2017) Colorectal cancer statistics, 2017. CA Cancer J Clin 67(3):177–193CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRefGoogle Scholar
  3. 3.
    Teng Y, Radde BN, Litchfield LM, Ivanova MM, Prough RA, Clark BJ, Doll MA, Hein DW, Klinge CM (2015) Dehydroepiandrosterone activation of G-protein-coupled estrogen receptor rapidly stimulates microRNA-21 transcription in human hepatocellular carcinoma cells. J Biol Chem 290(25):15799–15811CrossRefGoogle Scholar
  4. 4.
    Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH (2016) Hepatocellular carcinoma in Pakistan: national trends and global perspective. Gastroenterol Res Pract 2016:1–10CrossRefGoogle Scholar
  5. 5.
    Burnstock G (2006) Purinergic signalling. Br J Pharmacol 147(S1)Google Scholar
  6. 6.
    Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134(5):703–707CrossRefGoogle Scholar
  7. 7.
    Di Virgilio F (2012) Purines, purinergic receptors, and cancer. Cancer Res 72(21):5441–5447CrossRefGoogle Scholar
  8. 8.
    Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, Buell G (1994) A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature 371(6497):516–519CrossRefGoogle Scholar
  9. 9.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867CrossRefGoogle Scholar
  10. 10.
    Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 431(7007):405–406CrossRefGoogle Scholar
  11. 11.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444CrossRefGoogle Scholar
  12. 12.
    Gonzales E, Prigent S, Abou-Lovergne A, Boucherie S, Tordjmann T, Jacquemin E, Combettes L (2007) Rat hepatocytes express functional P2X receptors. FEBS Lett 581(17):3260–3266CrossRefGoogle Scholar
  13. 13.
    Emmett DS, Feranchak A, Kilic G, Puljak L, Miller B, Dolovcak S, McWilliams R, Doctor RB, Fitz JG (2008) Characterization of ionotrophic purinergic receptors in hepatocytes. Hepatology 47(2):698–705CrossRefGoogle Scholar
  14. 14.
    Dixit A, George J, Cheema H, Ryu Y, Dudeja V, Dawra R, Saluja A (2017) Extracellular ATP promotes systemic inflammation during acute pancreatitis. Gastroenterology 152(5):S896CrossRefGoogle Scholar
  15. 15.
    Greve A-S, Skals M, Fagerberg SK, Tonnus W, Ellermann-Eriksen S, Evans RJ, Linkermann A, Praetorius HA (2017) P2X1, P2X4, and P2X7 receptor knock out mice expose differential outcome of sepsis induced by α-haemolysin producing Escherichia coli. Front Cell Infect Microbiol 7Google Scholar
  16. 16.
    Draganov D, Gopalakrishna-Pillai S, Chen Y-R, Zuckerman N, Moeller S, Wang C, Ann D, Lee PP (2015) Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep 5:16222CrossRefGoogle Scholar
  17. 17.
    Khalid M, Brisson L, Tariq M, Hao Y, Guibon R, Fromont G, Mortadza SAS, Mousawi F, Manzoor S, Roger S (2017) Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells. Oncotarget 8(23):37278–37290CrossRefGoogle Scholar
  18. 18.
    Kawano A, Tsukimoto M, Mori D, Noguchi T, Harada H, Takenouchi T, Kitani H, Kojima S (2012) Regulation of P2X7-dependent inflammatory functions by P2X4 receptor in mouse macrophages. Biochem Biophys Res Commun 420(1):102–107CrossRefGoogle Scholar
  19. 19.
    Vázquez-Villoldo N, Domercq M, Martín A, Llop J, Gómez-Vallejo V, Matute C (2014) P2X4 receptors control the fate and survival of activated microglia. Glia 62(2):171–184CrossRefGoogle Scholar
  20. 20.
    Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA (2002) Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 168(12):6436–6445CrossRefGoogle Scholar
  21. 21.
    Li F, Guo N, Ma Y, Ning B, Wang Y, Kou L (2014) Inhibition of P2X4 suppresses joint inflammation and damage in collagen-induced arthritis. Inflammation 37(1):146–153CrossRefGoogle Scholar
  22. 22.
    Di Virgilio F, Ferrari D, Adinolfi E (2009) P2X7: a growth-promoting receptor—implications for cancer. Purinergic Signalling 5(2):251–256CrossRefGoogle Scholar
  23. 23.
    Sluyter R, Barden JA, Wiley JS (2001) Detection of P2X purinergic receptors on human B lymphocytes. Cell Tissue Res 304(2):231–236CrossRefGoogle Scholar
  24. 24.
    Li X, Qi X, Zhou L, Catera D, Rote NS, Potashkin J, Abdul-Karim FW, Gorodeski GI (2007) Decreased expression of P2X 7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol Oncol 106(1):233–243CrossRefGoogle Scholar
  25. 25.
    Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36(3):293–303CrossRefGoogle Scholar
  26. 26.
    Burnstock G (2006) Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58(1):58–86CrossRefGoogle Scholar
  27. 27.
    Stagg J, Smyth M (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29(39):5346–5358CrossRefGoogle Scholar
  28. 28.
    Besnard A, Gautherot J, Julien B, Tebbi A, Garcin I, Doignon I, Péan N, Gonzales E, Cassio D, Grosse B (2016) The P2X4 purinergic receptor impacts liver regeneration after partial hepatectomy in mice through the regulation of biliary homeostasis. Hepatology 64(3):941–953CrossRefGoogle Scholar
  29. 29.
    Azimi I, Beilby H, Davis FM, Marcial DL, Kenny PA, Thompson EW, Roberts-Thomson SJ, Monteith GR (2016) Altered purinergic receptor-Ca2+ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells. Mol Oncol 10(1):166–178CrossRefGoogle Scholar
  30. 30.
    Markwardt F, Schneider M, Prudic K, Pippel A, Klapperstück M, Müller C, Stolz M, Schumacher M, Schmalzing G (2017) Interaction of purinergic P2X4 and P2X7 receptor subunits. Biophys J 112(3):421aCrossRefGoogle Scholar
  31. 31.
    Schneider M, Prudic K, Pippel A, Klapperstück M, Braam U, Müller CE, Schmalzing G, Markwardt F (2017) Interaction of purinergic P2X4 and P2X7 receptor subunits. Front Pharmacol 8:860CrossRefGoogle Scholar
  32. 32.
    Csóka B, Németh ZH, Szabó I, Davies DL, Varga ZV, Pálóczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T (2018) Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. JCI insight 3(11)Google Scholar
  33. 33.
    Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hébuterne X, Gilson E, Schmid-Allilana A, Boyer O, Adriouch S (2015) Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res Canres 1778.2014Google Scholar
  34. 34.
    Hechler B, Gachet C (2015) Purinergic receptors in thrombosis and inflammation. Arterioscler Thromb Vasc Biol 35(11):2307–2315CrossRefGoogle Scholar
  35. 35.
    Khalid M, Manzoor S, Ahmad H, Asif A, Bangash TA, Latif A, Jaleel S (2018) Purinoceptor expression in hepatocellular virus (HCV)-induced and non-HCV hepatocellular carcinoma: an insight into the proviral role of the P2X4 receptor. Mol Biol Rep 1–6Google Scholar
  36. 36.
    Huang C-F, Yeh M-L, Tsai P-C, Hsieh M-H, Yang H-L, Hsieh M-Y, Yang J-F, Lin Z-Y, Chen S-C, Wang L-Y (2014) Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol 61(1):67–74CrossRefGoogle Scholar
  37. 37.
    Chitapanarux T, Phornphutkul K (2015) Risk factors for the development of hepatocellular carcinoma in Thailand. J Clin Transl Hepatol 3(3):182–188CrossRefGoogle Scholar
  38. 38.
    Künzli BM, Bernlochner M-I, Rath S, Käser S, Csizmadia E, Enjyoji K, Cowan P, d’Apice A, Dwyer K, Rosenberg R (2011) Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signalling 7(2):231–241CrossRefGoogle Scholar
  39. 39.
    Kim S-E, Paik HY, Yoon H, Lee JE, Kim N, Sung M-K (2015) Sex-and gender-specific disparities in colorectal cancer risk. World J Gastroenterol: WJG 21(17):5167–5175CrossRefGoogle Scholar
  40. 40.
    Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36(3):131–149CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Arun Asif
    • 1
  • Madiha Khalid
    • 1
  • Sobia Manzoor
    • 1
    Email author
  • Hassam Ahmad
    • 2
  • Aman Ur Rehman
    • 3
  1. 1.Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied BiosciencesNational University of Sciences and TechnologyIslamabadPakistan
  2. 2.Hepato-pancreatobiliary Liver Transplant UnitShaikh Zayd HospitalLahorePakistan
  3. 3.Department of HistopathologyShaikh Zayd HospitalLahorePakistan

Personalised recommendations